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Introduction
The dose-response relationship is central to clinical pharmacology. To establish the quantitative link between dose and drug effect, two main modelling approaches have been proposed and used depending on the availability of drug concentration samplings [1] [2] [3] [4] [5] [6] [7] [8] [9] . While some may argue for the necessity of the drug pharmacokinetics (PK) in its role to relate a dose to pharmacodynamics (PD) [2, 7, 9] , others advocate the possibility to predict PD directly from the dose, and drug concentration data, when available, is only treated as a covariate that can enhance the quality of this prediction [8] . The former approach was introduced with the belief that it could account for the dynamic evolution of therapeutic effect resulting from the time variation of drug concentrations, which, however, is not provided by the categorical value of a dose [10] . So, the resulting PK/PD models bridge the two formerly isolated disciplines of PK and PD, and allow a complete description of drug time-course effects. Considered nowadays the gold standard in pharmacometrics, the PK/PD modelling approach has been well implemented through the whole process of drug research and development, supported with rich blood samplings in the early phase studies.
For practical and economic reasons, a very limited number of blood samplings, e.g. one or two samples per individual in Phase III clinical trials, is a common situation. Moreover, patients' conditions, mainly in paediatrics, can restrict full access to multiple blood samplings. Hence, an alternative approach, which uses a virtual one-compartment PK model without entailing blood samplings, has been proposed to likely get around this issue [11] . Named as 'kinetics drug action models' or briefly K-PD models, this latter approach builds on the sole information of dose and PD [11] . K-PD models, advocated by several groups [8, 11, 12] , have been shown capable of providing a reasonable and cost-effective description of the dose-response relationship. From a modelling point of view, they are less computational and data demanding, and have drawn increasing interest from the practical milieu [8] . However, questions still arise in terms of their general use. For instance, given the rapidity and good prediction of the K-PD approach, under what conditions could it be used as a valuable alternative to the gold-standard PK/PD modelling approach? Moreover, when only very sparse PK information is available, is there an added value of PK/PD models compared to K-PD models? What is the minimum requirement in terms of PD information for the K-PD approach to become acceptable? These questions prompt the need for a thorough methodological investigation of the K-PD modelling approach. Thus, in the current paper, we aim to address these concerns and provide a scientific rationale for K-PD use. Considering the large number of sampling scenarios that should be included in such a study plan, which are not always feasible in practice, a modelling and simulation approach is adopted here to mimic real situations.
Methods

Model types and parameters
Two simultaneous PK/PD models, one of a linear elimination type and the other following a saturated Michaelis-Menten elimination, are used to assess the role of drug concentrations in the dose-response relationship. From each model, one dataset was simulated to serve as the data of reference. The PK was described by a one-compartment model structure. In the case of linear elimination, two parameters are involved: volume of distribution (V) and clearance (CL); in the case of Michaelis-Menten elimination, parameters include: V, maximum elimination rate of the system (V max ) and drug concentration producing 50% of the maximum elimination rate of the system (K m ). The PD was characterized with an indirect response model, in which the rate of response at baseline, or prior to drug administration, was described by:
where k s and k d are the zero-order rate and first-order constant for the production and loss of response R, respectively, and R 0 is the initial condition of the system. In the current paper, R is assumed to be measured in concentration units. Moreover, once the drug is administered, we assume an inhibitory effect on k s :
Further, this inhibition is assumed through the drug concentrations, C(t), modelled with an E max function. For the sake of simplicity, E max was supposed to be completely achieved with the administered dose and set to be 1. Then:
where EC 50 is the drug concentration that achieves half of the maximum effect. For the equivalent K-PD model, the inhibitory effect is described as [8] :
where IR is the drug elimination rate from the virtual compartment, EDK 50 is the drug elimination rate achieving half of the maximum effect. Again, E max was set to 1. If k DE is the elimination rate constant from the virtual compartment and A is the drug amount thereof, we have IR = k DE · A. In other words, compared to the real PK model, k DE can be considered as the ratio between CL and V, IR is the product of CL and C(t), and EDK 50 is equivalent to the product of EC 50 and CL. Figure 1 summarizes the correspondence between PK/PD and K-PD models used therein.
As usual for population PK models, the interindividual variability (IIV) of lognormal distribution is assumed for model parameters. For the jth individual, the PK parameter P j will have the following form:
where P* is the typical value for the population and η j is an independent and normally distributed random variable with zero-mean and variance ω 2 . Residual variability (RV) was modelled using an additive error model.
Study design and methodology
Two different scenarios were considered: one where the drug was assumed to exhibit saturated nonlinear elimination (nonlinear scenario) and another where the drug was assumed to have linear elimination (linear scenario). For each scenario a reference dataset was simulated using the model parameters provided in Table 1 . For the sake of simplicity, an intravenous bolus drug dose of 10 mg was assumed to be administered to each of 100 virtual patients for both scenarios. In the case of the drug with nonlinear elimination, a PK/PD model was fitted to the reference dataset containing 11 PK and 11 PD samples. From this dataset, the 11 PK samples were removed to generate the PD11 dataset to which a K-PD model was fitted. Individual predictions from both fitted models were then graphically compared. In the case of the linear elimination scenario, datasets of reduced PK/PD (PK5PD5, PK4PD4, PK3PD3, PK2PD3, PK1PD3, PK2PD2 and PK1PD2) and K-PD (PD5, PD4, PD3 and PD2) were extracted from the corresponding reference dataset. The number immediately after PK or PD refers to the number of PK and/or PD samples contained in each dataset. Based on the reference and reduced datasets, PK/PD and K-PD models were fitted, respectively. For both models, the estimated model parameters were then compared to those of the original PK/PD models used to simulate the reference data. Figure 2 provides an overview of this study design. Table 2 summarizes the different scenarios with the associated PK and PD sampling times where the samples were assumed to be collected.
Model selection criteria
Models were evaluated using the likelihood ratio test (LRT) (P = 0.001), along with other factors such as the reduction in the IIV and RV, the precision in parameter estimates, and the examination of goodness of fit (GOF) which consisted in six types of plots: (1) Mathematical equivalence between PK/PD and K-PD models. CL, clearance; V, volume of distribution; A, drug amount; iv, intravenous; C(t), drug concentration; EC 50 , concentration at which the effect is half of the maximum; PK, pharmacokinetics, PD, pharmacodynamics; K, kinetics; k DE , elimination rate from the virtual compartment (equivalent to the ratio of CL and V); EDK 50 , virtual infusion rate that leads 50% inhibition of k s (equivalent to the product of EC 50 and CL); IR, drug elimination rate from the virtual compartment (equivalent to the product of k DE and the amount therein) Table 1 Reference and estimated model parameters from the PK/PD and K-PD models for both nonlinear (NL) and linear elimination scenarios The need for information in K-PD vs. PK/PD approach errors (NPDE) vs. PRED, and (6) NPDE vs. time. Since a negligible amount (0.0001 mg l À1 ) was assumed as RV, the plot between the DV and IPRED (2) was used as visual evaluation in order to confirm that the most adequate model parameters were estimated. In this sense, when the correlation between DV and IPRED was almost 1, these parameters were considered to be well estimated.
Performance of different modelling approaches
For the nonlinear scenario, the time course of IPRED from the PK/PD and K-PD models were plotted on top of DV of the reference data for a visual inspection. The model with the smallest distance between IPRED and DV would be considered the best performing. For the linear scenario, in addition to the graphical assessment, the bias and root mean square error (RMSE) were computed using the following equations:
where θ ei is the estimated parameter value for the ith individual, θ ti represents the true original parameter value for Figure 2 Study design for both non-linear and linear cases Table 2 Summary of the sampling times schedule and performance index PI, performance index; PK/PD, population pharmacokinetics (PK) and pharmacodynamics (PD) model. For PK/PD models, the number refers to the number of PK and PD samples collected. NL, nonlinear scenario; K-PD, kinetics of drug action model. For K-PD models, the number represents the number of PD samples collected. NA, not applicable.
• Observation collected at that time
The need for information in K-PD vs. PK/PD approach the ith individual, and n is the number of individuals. The evaluated parameters were: k DE , k s , k d , and EDK 50 . For PK/PD models, k DE and EDK 50 were not estimated but computed as secondary parameters as: CL/V and EC 50 × CL, respectively. The ε-shrinkage (sh ε ) [13] was also used to evaluate the performance and was computed as:
where SD refers to the standard deviation and IWRES represents the individual weighted residuals.
In addition, we suggest, for K involved parameters, the use of the following performance index (PI) as a measurement of the global model performance:
where we define, for the kth parameter,
Here θ k,t represents the original model parameter value used to simulate the reference data, θ k,e refers to the median of the post hoc estimates from the estimated PK/PD or K-PD model; w k are weights we attribute to each parameter with ∑ K k¼1 w k ¼ 1; s ¼ 1 1Àshε ; and n c represents the number of components in PI. All components were equally weighted and no other weights were used. In all cases, K = 5 parameters were evaluated: k DE , k s , k d , EDK 50 . The total IIV, i.e. 0.18, is defined as the sum of IIV in CL (0.09) and V (0.09) in variance units. n c was included in the formula to facilitate the interpretation. Thus, PI can range from 0 (perfect performance) to ∞ (worst performance). Approaches with lower PI will be considered superior.
Software
Nonlinear mixed-effects modelling by extended least squares regression using the first-order conditional estimation (FOCE) was used to develop the PK/PD model using ADVAN 
Results
K-PD approach is not valid for drugs with nonlinear elimination
For the nonlinear scenario, our results strongly suggest that the K-PD approach is largely biased and not adequate to describe the data in comparison to the PK/PD approach, where a nonsignificant bias was found. The estimated parameters in PK11PD11 model were similar to those (original) used to simulate the reference data. Indeed, V m was only slightly underestimated by 3.5%. V, and the IIV in V, V m , K m , were overestimated by 6, 4.4, 12.5 and 4.4%, respectively. GOF plots showed random uniform scatter around the identity lines, indicating the absence of bias. Special attention should be paid to the scatterplot between DV and IPRED. Due to the negligible estimation of the PD RV (<0.003 mg l À1 ), almost a perfect correlation between DV and IPRED was observed ( Figure 3, panel A) . However for the K-PD approach, even though IIV was accounted for in both k DE and EDK 50 parameters, RV was not removed and cannot be neglected ( Figure 3, panel B) . Moreover, k s and k d were largely underestimated by 20.9 and 21.4%, respectively. In addition, panels C to H of Figure 3 show a comparison of the performance of IPRED between PK/PD and K-PD models for six randomly chosen individuals. In all the panels, orange and blue points represent IPRED for PK/PD and K-PD models, respectively. It is obvious that the PK/PD model gives a perfect prediction where we can observe that the orange line (IPRED) always crosses on top of the gray points (DV). This is further supported by the high correlation between DV and IPRED, which was estimated to be 0.996 (95% CI: 0.995-0.997). For the K-PD model, however, there are some subjects (i.e. 6, 22, 41, 55) whose IPRED are far away from the corresponding gray points, thus indicating a poor prediction. This is in agreement with the low correlation between DV and IPRED computed for the K-PD model: 0.423 (95% CI: 0.375-0.468). In Table 1 , the estimated model parameters from the PK/PD and K-PD models are reported as well as the original parameters used to simulate the reference data. The GOFs of both approaches are provided in the Supplementary material.
K-PD approach is only valid for drugs with linear elimination when a sufficient number of PD samples is available
For the linear scenario, a sequence of datasets with PK and PD samples progressively reduced was used to evaluate the suitability of K-PD vs. PK/PD models in describing the doseresponse relationship. All PK/PD and K-PD models constructed on these reduced datasets converged successfully with a number of significant digits higher than 3, no singularities and without zero gradients. The precision of the estimated parameters was also acceptable, with relative standard errors (RSE) < 30% and < 50% for fixed and random effects, respectively. In general, the predictions of K-PD models show larger RSE compared to PK/PD models. Except for the poorly estimated PK residual variability (RV) in PK1PD2 and in KPD2 (RSE of 56% and 141%, respectively), the estimated fixed and random effects in all models were always with low RSE (lower than 11 and 20%, respectively). The estimated parameters with the worst precision are: k s and EDK 50 in K-PD models, and CL and V in PK/PD models. In addition, it is important to note that the total IIV in K-PD models is always overestimated. All estimated model parameters are reported in Table 1 .
Conditional to the number of available PD samples, it turns out that the K-PD model can have a similar performance compared to the PK/PD models, which can be observed from the bias and RSME summarized in Figure 4 . When there are more than four PD samples, bias and RMSE are close to zero between the estimated PK/PD, K-PD parameters and the original true model parameters. When the number of samples is decreased to three, a slight difference in the estimated model parameters is observed. However, for the K-PD model, the estimation of k s and k d , which were underestimated by 4.63 and 4.50%, respectively, are likely more biased. When PD samples are further decreased to two, estimation biases of the K-PD model become evident for all parameters, clearly contrasting with PK/PD models. A simple computation shows that k s and k d were underestimated by 203%, EDK 50 was underestimated by 153%, while k DE was overestimated by 22%.
The PI results are displayed in Figure 5 and their values are summarized in Table 2 . For the sake of simplicity, all parameters were equally weighted. As can be observed, the Figure 3 Correlations between observations (DV) and individual predictions (IPRED) for the nonlinear scenario (panels A and B), and individual's model fit in six random subjects (panels C to H). Orange and blue points represent IPRED for PK/PD and K-PD models, respectively. Gray points represent real observations. Orange and blue lines represent IPRED from the best estimated PK/PD and K-PD mode, respectively
The need for information in K-PD vs. PK/PD approach performance of PK/PD and K-PD models degrades with the decrease in PD samples. Nevertheless, with the addition of 1 PK sample (PK1PD2) in KPD2, or 1 (PK1PD3) or 2 (PK2PD3) PK samples in KPD3, the bias and RSME were remarkably corrected as well as the PIs. These improvements with respect to the K-PD model through the addition of PK information are highlighted with red arrows in Figure 5 . It should be noted that, with the same number of PD samples, the PK/PD models always have PIs superior to those of the K-PD model. More interestingly, PK1PD2 has a better performance than KPD3, while PK1PD3 and PK2PD3 have a better performance than KPD4.
We also evaluated more complex effect models with different values of Hill constants γ (i.e. γ = 2 or 0.5 instead of 1). Under those conditions, the K-PD approach was not able to properly estimate γ no matter how many PD samples were used. Even with 11 PD samples (KPD11), γ was always underestimated. As a result, k DE and EDK 50 were always overestimated and underestimated, respectively, although k s and k d were well estimated in K-PD models when at least four PD samples were used. However, in accordance with our results, the addition of only one or two PK samples remarkably decreased bias and increased precision. These results are presented in the Supplementary material.
Figure 4
Bias and root squared mean error (RMSE) for k s , k d , k DE and EDK 50 depending on the number of PK and/or PD samples. In PK/PD models k DE was computed as the ratio between CL and V, while EDK 50 was computed as the product between EC 50 and CL. Orange refers to PK/PD model, dark green and green refer to PK/PD models with 2 or 1 PK samples, respectively. Blue represent K-PD models while the gray horizontal line represents the perfect value of bias and RMSE
Discussion
In the current paper, we aimed to investigate the performance and suitability of the K-PD approach in describing the doseresponse relationship when used as an alternative to the gold-standard PK/PD approach. It has been proved by different authors, particularly by Jacqmin et al. [8] , that the K-PD modelling based on (a virtual) one-compartment linear PK model is an acceptable and useful approach when there is a complete lack of PK concentrations. These authors proved that K-PD models are able to describe successfully the doseresponse relationship under a series of different conditions including, for example, a one compartment model with single and multiple doses, a two compartment model with active drug concentrations coming from central or peripheral compartment, and active metabolite formation. Thus, it is not the intention of the present work to go back to these issues. Nevertheless, we try to understand the conditions and the requirements for this approach to succeed. To make a fair evaluation, in silico protocols for drugs of nonlinear or linear eliminations were designed. For those drugs having nonlinear (Michaelis-Menten) elimination, our results suggest that K-PD models are not appropriate alternatives to the PK/PD approach. This is not surprising because the 'kinetic' parameters in a K-PD model, k DE and EDK 50 , are related to the linear PK parameters of the PK/PD model if a one compartment model with linear elimination after a bolus administration is assumed. In this sense, k DE is equivalent to the ratio between CL and V, and EDK 50 is equivalent to the product of EC 50 and CL. However, in the case of nonlinear elimination, this relationship cannot be maintained when nonlinear PK parameters such as V m and K m are introduced.
The K-PD model has the simplest structure compared to PK/PD models. Even with the assumption of the same model structure for PK/PD and K-PD and the same number of parameters to be estimated, different types and amounts of available Figure 5 Performance index. Orange refers to PK/PD model, dark green and green refer to PK/PD models with 2 or 1 PK samples, respectively. Blue represent K-PD models while the gray horizontal line represents the perfect value of the performance index. Red arrows represent the improvement in the performance index by the addition of 1 PK sample to the K-PD model
The need for information in K-PD vs. PK/PD approach observed data can make a difference. The observed data is restricted to PD data for the K-PD model, whereas PK and PD data are processed jointly by the traditional PK/PD model. Therefore, the same estimation quality of parameters requires at least the same quantity of information in terms of data used for the two modelling types. A heuristic mathematical explanation is attached in the Appendix to explain why more PD samples are required in K-PD than in PK/PD. More interestingly, it also explains why the performance of the K-PD approach with a limited number of PD samples (two or three), can be noticeably improved even if only one PK sample is added.
Our results suggest that two and three PD samples are not enough, and at least four PD samples should be needed to apply the K-PD approach. When two PD samples were used, the bias and RSME were high, and the estimated parameters were far from the original ones. In fact, k s and k d were drastically underestimated though the ratio between them remained relatively constant, a phenomenon already reported by other authors [8] . However, this bias could be easily corrected with the addition of just one PK sample. Similarly, the slight bias observed when three PD samples were used could also be corrected with the addition of one or two PK samples. All these indicate that K-PD models should not routinely replace PK/PD modelling. That being said, when the number of available PD samples was large enough, the K-PD approach could provide exceptional performance in terms of individual fitting, with an almost identical quality to the PK/PD approach. However, this is accompanied by an overestimation of the total IIV in the K-PD model as the IIV of CL is taken into account twice, as CL appears in two parameters (k DE and EDK 50 ). The larger the IIV in CL, the larger will be the overestimation.
We proposed PI as an index to compare the performance of the PK/PD and K-PD models. PI is based on the ratio between the true and estimated parameters, including fixed and random effects, while the value of sh ε is also accounted for. Thus, PI is expected to penalize the biases and possible overfitting. sh ε is included in PI because, for the informative data, IWRES distribution approaches a normal distribution with zero mean and unit variance. However, as data diminishes, the IWRES distribution shrinks towards zero. A shrinkage magnitude of zero indicates that the model is correctly fitted, while a value of 1 is an indicator of 'overfitting' [13] . Thus, the value of PI gives a simple and intuitive way to show good (PI close to 0) or poor (PI value far from 0) model performance. However, PI has its limitations. It can only be used qualitatively, and the numerical values of its difference cannot be used to judge the appropriateness of a model, even if a threshold is preset. In addition, PI should not be used out of this context.
In our analysis, not all the possible scenarios of reduced sampling times were evaluated. We assumed that sampling times did not affect model predictions. Our assumption is probably not true. However, for the selected sampling times used to run our simulations, the predictions were appropriate to describe the data. Therefore, in this particular case, our assumption of negligible impact of sampling times on the predictions cannot be rejected. This was probably true here because we had selected a relatively simple PK model (one compartment model with intravenous bolus administration and linear elimination). The performance observed under these conditions might not be extrapolated when more complex models are used. Under such circumstances, more than one PK sample may be needed, and also, the number of PD samples required for K-PD to have a similar performance compared to PK/PD models may vary. Despite the fact that other routes of administration (e.g. oral) can be easily implemented in a K-PD model, a larger number of PD samples might also be necessary. Thus, further analysis of the impact of the number of subjects, the level of IIV, the type of the model effect, the route of administration, and the source of variability (i.e. PD) should be performed. The latter is especially important as all the PD variability in the current exercise was assumed to be driven by the PK.
In conclusion, because of its simplicity and lesser data requirements, K-PD modelling may be used as a valuable alternative to the gold-standard PK/PD modelling in cases where the drug exhibits linear elimination and sufficiently large numbers of PD samples (≥4 per individual) are available. K-PD models should not be used in the cases of limited PD information and/or when the drug shows nonlinear elimination. Nevertheless, any addition of PK information might improve the performance of the K-PD approach as evidenced even in the extreme case of very sparse PK information, where PK/PD models have been proven to be superior to K-PD models. Therefore, whenever possible, the dose-response relationship should be described using a PK/PD model.
